Optimal therapeutic targeting by HDAC inhibition in biopsy-derived treatment-naïve diffuse midline glioma models.
H3 K27M-mutant (DMG)
diffuse intrinsic pontine glioma (DIPG)
diffuse midline glioma
histone deacetylase inhibitor (HDACi)
quisinostat
romidepsin
Journal
Neuro-oncology
ISSN: 1523-5866
Titre abrégé: Neuro Oncol
Pays: England
ID NLM: 100887420
Informations de publication
Date de publication:
25 03 2021
25 03 2021
Historique:
pubmed:
2
11
2020
medline:
28
4
2021
entrez:
1
11
2020
Statut:
ppublish
Résumé
Diffuse midline gliomas (DMGs), including diffuse intrinsic pontine gliomas (DIPGs), have a dismal prognosis, with less than 2% surviving 5 years postdiagnosis. The majority of DIPGs and all DMGs harbor mutations altering the epigenetic regulatory histone tail (H3 K27M). Investigations addressing DMG epigenetics have identified a few promising drugs, including the HDAC inhibitor (HDACi) panobinostat. Here, we use clinically relevant DMG models to identify and validate other effective HDACi and their biomarkers of response. HDAC inhibitors were tested across biopsy-derived treatment-naïve in vitro and in vivo DMG models with biologically relevant radiation resistance. RNA sequencing was performed to define and compare drug efficacy and to map predictive biomarkers of response. Quisinostat and romidepsin showed efficacy with low nanomolar half-maximal inhibitory concentration (IC50) values (~50 and ~5 nM, respectively). Comparative transcriptome analyses across quisinostat, romidepsin, and panobinostat showed a greater degree of shared biological effects between quisinostat and panobinostat, and less overlap with romidepsin. However, some transcriptional changes were consistent across all 3 drugs at similar biologically effective doses, such as overexpression of troponin T1 slow skeletal type (TNNT1) and downregulation of collagen type 20 alpha 1 chain (COL20A1), identifying these as potential vulnerabilities or on-target biomarkers in DMG. Quisinostat and romidepsin significantly (P < 0.0001) inhibited in vivo tumor growth. Our data highlight the utility of treatment-naïve biopsy-derived models; establishes quisinostat and romidepsin as effective in vivo; illuminates potential mechanisms and/or biomarkers of DMG cell lethality due to HDAC inhibition; and emphasizes the need for brain tumor-penetrant versions of potentially efficacious agents.
Sections du résumé
BACKGROUND
Diffuse midline gliomas (DMGs), including diffuse intrinsic pontine gliomas (DIPGs), have a dismal prognosis, with less than 2% surviving 5 years postdiagnosis. The majority of DIPGs and all DMGs harbor mutations altering the epigenetic regulatory histone tail (H3 K27M). Investigations addressing DMG epigenetics have identified a few promising drugs, including the HDAC inhibitor (HDACi) panobinostat. Here, we use clinically relevant DMG models to identify and validate other effective HDACi and their biomarkers of response.
METHODS
HDAC inhibitors were tested across biopsy-derived treatment-naïve in vitro and in vivo DMG models with biologically relevant radiation resistance. RNA sequencing was performed to define and compare drug efficacy and to map predictive biomarkers of response.
RESULTS
Quisinostat and romidepsin showed efficacy with low nanomolar half-maximal inhibitory concentration (IC50) values (~50 and ~5 nM, respectively). Comparative transcriptome analyses across quisinostat, romidepsin, and panobinostat showed a greater degree of shared biological effects between quisinostat and panobinostat, and less overlap with romidepsin. However, some transcriptional changes were consistent across all 3 drugs at similar biologically effective doses, such as overexpression of troponin T1 slow skeletal type (TNNT1) and downregulation of collagen type 20 alpha 1 chain (COL20A1), identifying these as potential vulnerabilities or on-target biomarkers in DMG. Quisinostat and romidepsin significantly (P < 0.0001) inhibited in vivo tumor growth.
CONCLUSIONS
Our data highlight the utility of treatment-naïve biopsy-derived models; establishes quisinostat and romidepsin as effective in vivo; illuminates potential mechanisms and/or biomarkers of DMG cell lethality due to HDAC inhibition; and emphasizes the need for brain tumor-penetrant versions of potentially efficacious agents.
Identifiants
pubmed: 33130903
pii: 5948533
doi: 10.1093/neuonc/noaa249
pmc: PMC7992886
doi:
Substances chimiques
Histones
0
Panobinostat
9647FM7Y3Z
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
376-386Subventions
Organisme : NCI NIH HHS
ID : R01 CA114567
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
© The Author(s) 2020. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
Sci Rep. 2020 Apr 2;10(1):5798
pubmed: 32242081
J Neurosurg Pediatr. 2018 Sep;22(3):288-296
pubmed: 29856296
Neuro Oncol. 2018 Oct 9;20(11):1547-1555
pubmed: 29741745
Neuro Oncol. 2017 Sep 1;19(9):1279-1280
pubmed: 28821206
J Physiol. 1991 Aug;439:215-37
pubmed: 1895237
Cancer Chemother Pharmacol. 2018 Sep;82(3):493-503
pubmed: 29987369
Exp Hematol. 2012 Jul;40(7):564-74
pubmed: 22381681
Pediatr Neurosurg. 1990-1991;16(2):73-83
pubmed: 2132928
Neurol Res. 2019 Nov;41(11):1043-1049
pubmed: 31556357
J Cell Biochem. 2009 Jul 1;107(4):600-8
pubmed: 19459166
Neuro Oncol. 2014 Oct;16 Suppl 4:iv1-63
pubmed: 25304271
Int J Mol Sci. 2019 Jul 16;20(14):
pubmed: 31315202
Int J Hematol. 2017 Nov;106(5):655-665
pubmed: 28664499
Cold Spring Harb Perspect Biol. 2014 Apr 01;6(4):a018713
pubmed: 24691964
Leuk Lymphoma. 2018 Dec;59(12):2904-2910
pubmed: 29616865
Sci Transl Med. 2019 Nov 20;11(519):
pubmed: 31748226
Neurosurgery. 1993 Dec;33(6):1026-9; discussion 1029-30
pubmed: 8133987
Cancer Cell. 2019 Nov 11;36(5):528-544.e10
pubmed: 31631026
J Thorac Oncol. 2010 Oct;5(10):1644-8
pubmed: 20871263
JAMA Otolaryngol Head Neck Surg. 2016 Apr;142(4):330-8
pubmed: 26892902
Mol Carcinog. 2018 Feb;57(2):167-181
pubmed: 28940371
Life Sci. 2018 Sep 1;208:161-166
pubmed: 30031058
Science. 2020 Jan 3;367(6473):45-51
pubmed: 31806696
Exp Neurol. 2019 Feb;312:33-42
pubmed: 30452905
Cancer Med. 2016 Nov;5(11):3041-3050
pubmed: 27748045
Cancer Cell. 2017 May 8;31(5):635-652.e6
pubmed: 28434841
J Mol Diagn. 2014 Jan;16(1):56-67
pubmed: 24189654
Bioinformatics. 2013 Apr 15;29(8):1035-43
pubmed: 23428641
Nat Genet. 2012 Jan 29;44(3):251-3
pubmed: 22286216
Clin Exp Metastasis. 2017 Apr;34(3-4):229-239
pubmed: 28289921
Mol Biol Rep. 2020 Jan;47(1):433-441
pubmed: 31637620
J Gene Med. 2020 Feb;22(2):e3152
pubmed: 31830337
PLoS One. 2015 Mar 06;10(3):e0118926
pubmed: 25748921
Curr Pharm Des. 2011 Dec;17(38):4362-71
pubmed: 22204434
Clin Cancer Res. 2013 Aug 1;19(15):4262-72
pubmed: 23741066
Trends Cell Biol. 2008 Jun;18(6):291-7
pubmed: 18472263
Curr Treat Options Neurol. 2019 Jul 10;21(8):37
pubmed: 31290035
Am J Physiol Cell Physiol. 2013 Dec 15;305(12):C1230-9
pubmed: 24025866
Cancer Cell Int. 2017 Oct 13;17:90
pubmed: 29046615
J Cell Mol Med. 2018 Dec;22(12):6190-6201
pubmed: 30255547
Blood. 2012 Nov 15;120(20):4215-8
pubmed: 22955928
Blood. 2011 Mar 31;117(13):3658-68
pubmed: 21292776
Nature. 2012 Jan 29;482(7384):226-31
pubmed: 22286061
BMC Neurol. 2013 Dec 27;13:210
pubmed: 24370119
Nat Med. 2018 Nov;24(11):1752-1761
pubmed: 30349086
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
J Clin Oncol. 2011 Oct 10;29(29):3852-61
pubmed: 21911727
Science. 2014 Aug 29;345(6200):1065-70
pubmed: 25170156
Nat Med. 2015 Jun;21(6):555-9
pubmed: 25939062
Cell Biochem Biophys. 2015 Nov;73(2):389-392
pubmed: 27352327